This content is for healthcare professionals only.

This activity is funded by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals.

This activity is jointly provided by USF Health and touchIME.

Faculty & Disclosures

Listen on the go
    • Downloads
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Dr Elaine Siegfried

    Cardinal Glennon Children’s Hospital, St. Louis, MO, USA

    Elaine Siegfried is director of the Division of Pediatric Dermatology at the Cardinal Glennon Children’s Hospital, Saint Louis University Health Sciences Center, MO, USA. She is also the owner and director of Kids Dermatology, St. Louis, USA. read more

    Dr Siegfried is a past president of the American Board of Dermatology, a founding member of the Pediatric Dermatology Research Alliance and chair of the Emerging Practice Models Committee at the American Academy of Dermatology. She is also a member or fellow of a number of other professional organizations, including the Society for Pediatric Dermatology and the American Dermatological Association. She has volunteered her services for many years as a member of scientific advisory boards for the National Eczema Association and the National Foundation for Ectodermal Dysplasia.

    Dr Siegfried has authored approximately 130 journal papers and 20 book chapters, and served as principal investigator for more than 50 clinical trials.

    Dr Elaine Siegfried discloses: Speaker Bureau fees from: Regeneron, Sanofi Genzyme and Verrica. Consulting fees from: AbbVie, Alphyn, ASLAN Pharmaceuticals, Boehringer Ingelheim, Cara Therapeutics, Incyte, Leo, NobelPharma, Novan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi Genzyme, UCB and Verrica. Contracted research: AI Therapeutics. Clinical trials (all fees to institution): Amgen, Janssen, Lilly, Pierre Fabre, Regeneron, Sanofi and Verrica. Data safety monitoring board: Espere Healthcare, Leo, Novan, Pfizer and UCB. 
    Assist. Prof. Nives Pustišek

    Children’s Hospital Zagreb, Croatia

    Nives Pustišek is an assistant professor and head of the Department of Dermatology and Venereology, Gynecology and Reproductive Health at Children’s Hospital Zagreb, Croatia. read more

    Dr Pustišek is a renowned dermatologist and venereologist, and a specialist in the field of paediatric dermatology. She is particularly active in the areas of atopic dermatitis and psychodermatology, with a focus on improving the quality of life for patients and their families through educational programmes. 

    Dr Pustišek has published numerous articles in peer-reviewed medical journals and presented at international conferences.

    Dr Nives Pustišek discloses: Speaker’s Bureau: AbbVie, Bayer, Bioderma, LEO Pharma, L’Oreal Adria, Novartis, Oktal Pharma, Pfizer and Sanofi-Aventis.
    Prof. Andreas Wollenberg

    Ludwig-Maximilian University, Munich, Germany

    Andreas Wollenberg is a professor of dermatology and allergy at the Ludwig-Maximilian University in Munich, Germany. He is also affiliated with the University Hospital Augsburg, Germany. read more

    Prof. Wollenberg has conducted research in the field of atopic dermatitis, experimental dermatology, dendritic cell research, eczema herpeticum, perioral dermatitis and epidermal growth factor receptor inhibitor-induced skin toxicity. His research has generated more than 340 peer-reviewed publications. 

    Prof. Wollenberg is a member of the editorial board of the Journal of the European Academy of Dermatology and Venerology, and a reviewer for many biomedical journals. Prof. Wollenberg has served as head of the European Task Force on Atopic Dermatitis (ETFAD) for 10 years, and is the lead author of the ETFAD Position Paper on AD management. Moreover, he is the lead author of the current EuroGuiDerm Guidelines for Atopic Dermatitis. Prof. Wollenberg is an executive board member and secretary of the International Society of Atopic Dermatitis.

    Prof. Andreas Wollenberg discloses: Advisory Board or Panel: AbbVie, Aileens, Almirall, Amgen, BMS, Galderma, Glenmark, GSK, Hans Karrer, Kyowa Kirin, Janssen, Leo Pharma, Eli Lilly, L’Oreal, MSD, Mylan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi-Aventis and UCB. Consultancy fees from: AbbVie, Aileens, Almirall, Amgen, Beiersdorf, Bioderma, Bioproject, BMS, Galderma, GSK, Hans Karrer, Kyowa Kirin, Janssen, Leo Pharma, Eli Lilly, L’Oreal, MSD, Mylan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Sanofi-Aventis and UCB. Grants/Research Support from: Leo Pharma (relationship terminated) and Pierre Fabre. Salary, Contractual Services from: Pierre Fabre. Speaker’s Bureau: AbbVie, Almirall, Amgen, Beiersdorf, Bioderma, Bioproject, BMS, Galderma, Glenmark, GSK, Hans Karrer, Kyowa Kirin, Janssen, Leo Pharma, Eli Lilly, L’Oreal, Maruho, MedImmune, MSD, Mylan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi-Aventis and UCB.
    Back to Faculty
    touchIMMUNOLOGY touchIMMUNOLOGY
    Dr Elaine Siegfried

    Cardinal Glennon Children’s Hospital, St. Louis, MO, USA

    CHAIR
    Panelists:
    Assist. Prof. Nives Pustišek, Prof. Andreas Wollenberg
    Start activity
     
    Videos Take CE/CME Test
    Paediatric Dermatology, Atopic Dermatitis, Dermatological Conditions, Immunology CE/CME accredited

    touchPANEL DISCUSSION
    A visually engaging discussion designed to emulate a ‘live’ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity. Close

    Paediatric atopic dermatitis: Evolving strategies for improved management

    Faculty Podcast Featured
    Useful tips
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Recognize the burden of atopic dermatitis in children, their families and caregivers and its impact on quality of life, particularly in moderate-to-severe disease
    • Summarize the latest data for systemic treatment options in children and adolescents with moderate-to-severe atopic dermatitis
    • Assess how continuity of care in children and adolescents impacts long-term symptom control
    Overview

    In this activity, three experts discuss the burden of atopic dermatitis in children and their families, how to assess it in the clinic, and when treatment escalation with systemic therapy should be considered. They also explore how clinicians can support paediatric patients and their families to achieve long-term control of atopic dermatitis and optimize treatment outcomes.

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    Dermatologists, allergists and immunologists, nurses, dermatology nurse practitioners, primary care physicians and paediatricians involved in the management of paediatric atopic dermatitis

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Dr Elaine Siegfried discloses: Speaker Bureau fees from: Regeneron, Sanofi Genzyme and Verrica. Consulting fees from: AbbVie, Alphyn, ASLAN Pharmaceuticals, Boehringer Ingelheim, Cara Therapeutics, Incyte, Leo, NobelPharma, Novan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi Genzyme, UCB and Verrica. Contracted research: AI Therapeutics. Clinical trials (all fees to institution): Amgen, Janssen, Lilly, Pierre Fabre, Regeneron, Sanofi and Verrica. Data safety monitoring board: Espere Healthcare, Leo, Novan, Pfizer and UCB. 

    Dr Nives Pustišek discloses: Speaker’s Bureau: AbbVie, Bayer, Bioderma, LEO Pharma, L’Oreal Adria, Novartis, Oktal Pharma, Pfizer and Sanofi-Aventis.

    Prof. Andreas Wollenberg discloses: Advisory Board or Panel: AbbVie, Aileens, Almirall, Amgen, BMS, Galderma, Glenmark, GSK, Hans Karrer, Kyowa Kirin, Janssen, Leo Pharma, Eli Lilly, L’Oreal, MSD, Mylan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi-Aventis and UCB. Consultancy fees from: AbbVie, Aileens, Almirall, Amgen, Beiersdorf, Bioderma, Bioproject, BMS, Galderma, GSK, Hans Karrer, Kyowa Kirin, Janssen, Leo Pharma, Eli Lilly, L’Oreal, MSD, Mylan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Sanofi-Aventis and UCB. Grants/Research Support from: Leo Pharma (relationship terminated) and Pierre Fabre. Salary, Contractual Services from: Pierre Fabre. Speaker’s Bureau: AbbVie, Almirall, Amgen, Beiersdorf, Bioderma, Bioproject, BMS, Galderma, Glenmark, GSK, Hans Karrer, Kyowa Kirin, Janssen, Leo Pharma, Eli Lilly, L’Oreal, Maruho, MedImmune, MSD, Mylan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi-Aventis and UCB.

    Content reviewer

    Ann Lin, MD, Peer Reviewer has no financial interests/relationships or affiliations in relation to this activity.

    Touch Medical Director

    Adriano Boasso has no financial interests/relationships or affiliations in relation to this activity.

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu.

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Date of original release: 07 December 2023. Date credits expire: 07 December 2024.

    If you have any questions regarding credit please contact cpdsupport@usf.edu.

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    CONFERENCE HUB

    Melinda Gooderham, Dermatology Meeting News 2023: Deucravacitinib efficacy by baseline characteristic in moderate to severe plaque psoriasis

    GO TO HUB

    JOURNALS

    Foreword – touchREVIEWS in RMD Vol 1 Issue 2 – 2022

    GO TO ARTICLE

    touchPANEL DISCUSSION

    The practicalities of eosinophilic oesophagitis management: A closer look at emerging biologic treatment options

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    JOURNALS

    Foreword – touchREVIEWS in RMD Vol 1 Issue 1 – 2022

    GO TO ARTICLE

    touchTALKS

    Growing up with atopic dermatitis: Achieving sustained outcomes for moderate-to-severe disease

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Amy S. Paller, Dermatology Meeting News: Dupilumab LIBERTY AD PEDS Trial

    GO TO HUB

    Topics covered in this activity

    Paediatric Dermatology / Atopic Dermatitis / Dermatological Conditions / Immunology
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 9 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This activity is funded by:

    An independent medical education grant from Sanofi and Regeneron Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 7 December 2023. Date credits expire: 7 December 2024.

    Claim Credit
    touchPANEL DISCUSSION
    Paediatric atopic dermatitis: Evolving strategies for improved management
    0.75 CE/CME credit
    Question 1/5
    Which of the following is considered an important indicator of the severity of atopic dermatitis?

    Children with atopic dermatitis suffer from sleep disturbance that worsens with increased disease severity.1 It is mainly caused by nocturnal itching and scratching behaviour, skin-related pain and skin-related fearful thoughts,2 influencing other aspects of daily life that leads to a negative impact on the quality of life.

    References

    1. Fishbein AB, et al. J Am Acad Dermatol. 2023;88:348–56.
    2. Cameron S, et al. Allergy. 2023; doi: 10.1111/all.15818.
    Question 2/5
    Which of the following conditions would you exclude before recommending targeted systemic therapy for your 6-year-old patient with suspected atopic dermatitis that is refractory to topical treatment?

    Primary immunodeficiencies can mimic refractory atopic dermatitis.1 Systemic therapy for atopic dermatitis includes immunosuppressive drugs, biologics and Janus kinase inhibitors targeting the immune system that can worsen primary immunodeficiencies.2,3

    References

    1. Izadi N, Leung DYM. Ann Allergy Asthma Immunol. 2018;120:23–33.
    2. Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2022;36:1409–31.
    3. Tsuji G, et al. Biomedicines. 2023;11:1303.
    Question 3/5
    Based on regulatory agency approvals (as of November 2023), which of the following systemic treatments would you consider for your patients with atopic dermatitis who are ≤6 years old?

    Dupilumab is approved by the FDA and EMA for the treatment of severe atopic dermatitis in patients 6 months or older who are candidates for systemic therapy.1,2 Lebrikizumab3, tralokinumab1,2 and upadacitinib1,2 are indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents ≥12 years who are candidates for systemic therapy.

    Abbreviations

    EMA, European Medicines Agency; FDA, US Food and Drug Administration.

    References

    1. EMA. Available at: www.ema.europa.eu/en/medicines; SmPCs searchable by drug name (accessed 3 November 2023).
    2. FDA. Available at: www.accessdata.fda.gov/scripts/cder/daf/index.cfm; PIs searchable by drug name (accessed 3 November 2023).
    3. EMA. Lebrikizumab: Summary of opinion. Available at: www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ebglyss_en.pdf (accessed 3 November 2023).
    Question 4/5
    Your 17-year-old female patient with atopic dermatitis reports increasingly worse itch, particularly at night, despite daily use of a high-potency topical corticosteroid. She has concerns about using an injectable medication and the need for blood tests. How do you advise her about the requirements for JAK inhibitors (abrocitinib, baricitinib and upadacitinib) and targeted biologics (dupilumab, lebrikizumab and tralokinumab)?

    JAK, Janus kinase.

    Biologics are available as injections for the treatment of atopic dermatitis, typically dosed every 2–4 weeks. They do not require regular laboratory monitoring.1 JAK inhibitors are available as oral formulations and can be useful for short-term, episodic treatment but have safety concerns, especially in paediatric patients with long-term treatment needs.1 The European guideline (EuroGuiDerm) on atopic eczema recommends baseline screening (full blood count, renal, liver and lipid profile, creatinine phosphokinase levels, and hepatitis and TB tests) prior to treatment initiation with JAK inhibitors, and regular monitoring while on therapy.2

    Abbreviations

    JAK, Janus kinase; TB, tuberculosis.

    References

    1. Butala S, Paller AS. J Allergy Clin Immunol. 2023;151:681–5.
    2. Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2022;36:1409–31.

     

    Question 5/5
    Your 14-year-old male patient with severe atopic dermatitis achieved control of his skin disease 6 months after starting tralokinumab therapy. His parents are currently administering the injections but he would like to self-inject. What do you recommend?

    Tralokinumab can be self-injected by the patient or their caregiver, as determined appropriate by a healthcare professional.1 Proper training should be provided to patients or caregivers on the administration of tralokinumab prior to use.1 Self-management should be encouraged as it can improve adherence to the treatment plan, thereby improving health-related outcomes in chronic conditions.2

    References

    1. EMA. Tralokinumab SmPC. 30 October 2023. Available at: www.ema.europa.eu/en/medicines (accessed 3 November 2023).
    2. Lozano P, Houtrow A. Paediatrics. 2018;141:e20171284.
    Back to Activity

    You may also be interested in...

    JOURNALS

    Foreword – touchREVIEWS in RMD Vol 1 Issue 2 – 2022

    GO TO ARTICLE

    JOURNALS

    Foreword – touchREVIEWS in RMD Vol 1 Issue 1 – 2022

    GO TO ARTICLE

    CONFERENCE HUB

    Afsaneh Alavi, Dermatology Meeting News 2022: Phase 2 Trial of Vilobelimab for Ulcerative Pyoderma Gangrenosum

    GO TO HUB

    touchEXPERT OPINIONS

    Navigating the emerging complexities of melanoma treatment: New insights for clinical practice

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchPANEL DISCUSSION

    Paving the way for optimal disease control in moderate-to-severe type 2 asthma

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Giovanni Damiani, EADV 2020 – Highlights from the meeting

    GO TO HUB
    This activity is funded by:

    An independent medical education grant from Sanofi and Regeneron Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 7 December 2023. Date credits expire: 7 December 2024.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup